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Ligand-mediated activation of toll-like receptors (TLRs) not only induces inflammation
but also immune suppression, which is an emerging area of investigation. Multiple
negative feedback intracellular mechanisms have been described that are brought into
play to prevent uncontrolled TLR activation. However, the identification of TLR-induced
regulatory myeloid cells is a relatively recent development that has ramifications in
pathogen-induced disease state as well as in cancer. Our efforts to understand how
a high dose of lipopolysaccharide (LPS), a ligand of TLR4, suppresses allergic airway
inflammation led to the identification of myeloid cells that are CD11b+Griint(Ly6Gint)F4/80+
and are phenotypically and morphologically similar to myeloid-derived suppressor cells
(MDSCs) which are best studied in the context of cancer. MDSCs have been also
detected during infection by various bacteria, parasites and viruses, which can engage
different TLRs. These TLR-induced myeloid cells produce different types of mediators to
influence immune response and inflammation that can be either beneficial or detrimental
to the host. One beneficial function of TLR4/MyD88-triggered MDSCs in the lung
is to efferocytose apoptotic neutrophils to help resolve inflammation elicited during
bacterial pneumonia. A better understanding of the generation and function of these
regulatory cells would be helpful to harness their potential or suppress their function for
disease-specific immune regulation.
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Microorganism-associated molecular patterns are recognized by
pattern-recognition receptors such as Toll-like receptors (TLRs),
NOD-like receptors and RIG-I-like receptors in different cells
of infected hosts to initiate a rapid innate immune response
as the first step in defense against the invading pathogen. The
innate immune response, in turn, induces an appropriate adap-
tive immune response to effectively protect the host with the
establishment of a memory response for a rapid recall response
during subsequent exposure to the pathogen. After the identi-
fication of the toll protein in Drosophila as an essential host-
defense mechanism in an organism that lacks the adaptive
immune system (Lemaitre et al., 1996), TLR4 was the first TLR
to be identified in mammals (Medzhitov et al., 1997; Poltorak
et al., 1998; Qureshi et al., 1999). The desire to identify a
counterpart to the Drosophila Toll in the mammalian system
was largely driven by the need to understand the pathogen-
esis of bacterial infection-induced sepsis syndrome (Rittirsch
et al., 2008). Thus, lipopolysaccharide (LPS), a component of
the outer membrane of Gram-negative bacteria, was identi-
fied as a ligand of TLR4. Since then, 10 and 12 functional
TLRs have been characterized in humans and mice, respectively
(Kawai and Akira, 2010). In addition to bacterial LPS, the TLR4
complex is triggered by multiple additional ligands. This pro-
cess ultimately results in downstream activation of NF-κB or
IRF-1 via the adaptors MyD88 and TRIF to induce transcrip-
tion of cytokine and chemokine genes and a host of other
genes that collectively ramp up the host’s immune defense
mechanisms.
REGULATION OF TLR-INDUCED INTRACELLULAR
RESPONSES
Although TLR induced pro-inflammatory response is crucial for
the elimination of the invading pathogen, uncontrolled immune
activation leads to collateral tissue damage. Therefore, stringent
negative feedback is necessary to temper TLR-induced signaling
in target cells. These measures include a range of extracellular
and intracellular decoy receptors, membrane-bound suppressors,
intracellular negative regulators, degradation of TLRs, and TLR-
induced apoptosis (Liew et al., 2005; Kondo et al., 2012). A dis-
tinct TLR-induced immunosuppressive mechanism in different
organs, as discovered in some laboratories including our own, is
the development of myeloid-derived suppressor cells (MDSCs).
In this review, we will discuss the characteristics of MDSCs
induced by TLR agonists such as LPS and by pathogens and
the emerging field of MDSC-mediated suppression of immune
responses.
DEVELOPMENT OF A REGULATORY MYELOID CELL, MDSC,
BY LPS-TLR4 SIGNALING TO CONTROL IMMUNE
RESPONSES
LPS exerts differential effects on immune responses in the lung
depending on the dose. In the context of exposure to the model
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allergen ovalbumin (OVA), a very low dose (< 1 ng) of LPS does
not induce adaptive immunity and instead tolerance to OVA
develops (Oriss et al., 2005). An intermediate dose (100 ng) of
LPS induces a Th2-biased response to OVA and promotes aller-
gic airway inflammation (Eisenbarth et al., 2002). Higher doses of
LPS (1–100μg), however, inhibit allergic inflammation (Gerhold
et al., 2002, 2008; Rodriguez et al., 2003; Delayre-Orthez et al.,
2005). Our efforts to understand the mechanism(s) by which a
high dose of LPS inhibits allergic airway inflammation led to the
discovery of a new role for the MDSC as a TLR4/MyD88- but not
TRIF-induced cell type that can influence T cell responses in the
lung (Arora et al., 2010). Figure 1 illustrates the induction of lung
MDSCs in response to LPS or bacterial infection and the function
of these cells in the lung tissue.
In mice, MDSCs are uniformly characterized as CD11b+Gr1+
cells. Since anti-Gr1 recognizes both the Ly6G and Ly6C epi-
topes, use of antibodies with monospecificity toward one or the
other has shown differential expression of these molecules on
different types of MDSCs. Typically, CD11b+Ly6Chigh MDSCs
are mononuclear and considered to be monocytic (Mo-MDSC)
while CD11b+Ly6G+Ly6Clow/− MDSCs consist of multilobed
nuclei and represent granulocytic or neutrophilic MDSCs (PMN-
MDSC). Additional cell surface molecules including the α-
chain of the receptor for IL-4 and IL-13 (CD124), the mouse
macrophage-expressed molecule, F4/80, M-CSF-1R or c-fms
(CD115) and the costimulatory molecule CD80 have also been
identified in different combinations on some subsets of MDSCs
(Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha,
2009; Peranzoni et al., 2010). LPS-induced MDSCs in the lung
have the phenotype CD11b+Ly6GintLy6Clow/−F4/80+CD80+.
Much before LPS was shown to be a stimulus for MDSC accu-
mulation, multiple factors, associated with chronic inflammation
and cancer such as VEGF, GM-CSF, G-CSF, IL-1β, IL6, and
PGE2 were described as inducers of MDSCs (Gabrilovich and
Nagaraj, 2009). However, the cell surface phenotype andmediator
employed by theMDSCs induced by the various types of agents to
suppress immune responses are not the same as discussed below.
LPS-INDUCED LUNG MDSCs ARE TISSUE RESIDENT AND
CAN SUPPRESS EFFECTOR T CELL FUNCTION
A previous study described proliferation ofmigratory hematopoi-
etic stem and progenitor cells (HSPCs) within extramedullary
tissues in response to LPS (Massberg et al., 2007). Although
∼70% of the myeloid cells generated in the presence of LPS
expressed the dendritic cell (DC)marker CD11c, a subset of lower
frequency (10%) expressed Gr1 at intermediate to high levels and
may have been related to MDSCs. In our study, after infusion of
GFP+ lineageneg (lin−) bone marrow progenitor cells into naïve
mice, LPS instillation into the lungs promoted the accumulation
of GFP+CD11b+Gr1int(Ly6Gint) cells in the lung tissue (Arora
et al., 2010).
LPS-induced Gr1int cells lack CCR7, which is essential for
the migration to lymph nodes (Debes et al., 2005). LPS-induced
Gr1int cells were not detectable in the lung-draining lymph nodes
(LNs) and have been largely identified as tissue-dwelling cells
(Arora et al., 2010; Poe et al., 2013). The earlier study also showed
that LPS stimulation not only enhances the local proliferation
and differentiation of HSPCs but also reduces the migratory
capacity of HSPCs within extramedullary tissues by interfering
with S1P-S1P1-dependent signaling (Massberg et al., 2007). It
was similarly shown in vitro that incubation of HSPCs with TLR
ligands triggers HSPC proliferation and rapid myeloid differen-
tiation (Nagai et al., 2006). Intradermal injection of Salmonella
typhimurium or LPS was shown to induce a potent local innate
FIGURE 1 | Induction of MDSCs in the lung in response to a high dose of LPS or bacterial infection. The lung MDSCs express Arg1 and produce IL-10 and
suppress Th2 effector function in the context of allergic airway inflammation and phagocytose apoptotic neutrophils during bacterial pneumonia.
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inflammatory response that blocked DC differentiation and
migration to the draining LNs (Rotta et al., 2003).
MDSCs are well-known for their ability to inhibit T-cell pro-
liferation and immune responses (Nagaraj et al., 2013). MDSCs
utilize multiple mechanisms to exert their suppressive functions
and recent studies suggest communication between MDSCs and
T cells which is not just limited to cancer but to different types
of inflammation-associated conditions which has been compre-
hensively reviewed recently (Nagaraj et al., 2013). The best-
described mechanisms/mediators related to immunosuppression
by MDSCs include expression of Arginase 1, nitric oxide, per-
oxynitrite and reactive oxygen species. MDSCs can also block
T-cell activation by deprivation of L-cysteine, an essential amino
acid required for T-cell activation and function (Srivastava et al.,
2010). Various other mechanisms used by MDSCs to suppress
immune responses have also been suggested which include upreg-
ulation of cyclooxygenase 2 and prostaglandin E2 (Rodriguez
et al., 2005), secretion of TGF-β (Yang et al., 2008; Filipazzi et al.,
2012) and induction of Tregs (Huang et al., 2006; Serafini et al.,
2008; Nagaraj et al., 2013). Our study showed that the IL-10/Arg1
axis is involved in the suppressive activity of lung MDSCs on
Th2 cells (Arora et al., 2010). In another study, HO-1 was impli-
cated in the suppression of alloreactive responses by LPS-induced
MDSCs (De Wilde et al., 2009). HO-1 was previously shown to
promote IL-10 expression and conversely IL-10 can induce HO-1
expression (Ricchetti et al., 2004; Chauveau et al., 2005). In view
of the diversity of immune signals to which MDSCs are exposed
in different biological contexts, it is expected that the mecha-
nism of suppression by MDSCs induced by various agents would
also vary.
Our study has shown that after repeated exposure of mice
to LPS, the MDSCs accumulate with a delayed kinetics in the
lung tissue and their numbers increase significantly over base-
line only 3 days after LPS instillation once every day (Poe et al.,
2013). Since the MDSCs in the lung remain in the tissue after
each LPS instillation unlike dendritic cells (DCs) which traffic
readily to the LNs (Arora et al., 2010), this differential response
causes selective enrichment of the MDSCs over DCs in the tis-
sue (Arora et al., 2010). The LPS/TLR4-induced lung MDSCs
suppress the ability of lung DCs to promote Th2 cytokine produc-
tion, upregulate GATA-3 or induce STAT5 activation in primed
Th2 cells, both transcription factors being critical in Th2 effec-
tor function (Zhang et al., 1997; Zheng and Flavell, 1997; Zhu
et al., 2003). Since STAT5 activation promotes T cell viability
(Wofford et al., 2008; Hand et al., 2010), it is possible that lung
MDSCs compromise Th2 cell survival thereby reducing the size
of the memory T cell pool (Hu et al., 2001; De Wilde et al.,
2009). Thus, collectively, it appears that an important effector
function of TLR-induced MDSCs is not directed to the LN to
influence the development of adaptive immune functions but
to control immune responses in the tissue. Of note, flagellin
(TLR5)-induced MDSCs have been identified in the lung in the
context of cystic fibrosis and associated infection by Pseudomonas
aeruginosa (Rieber et al., 2012). Although it is proposed that
these MDSCs may inhibit T cell responses against the bacteria
based on the ability of the cells to inhibit T cell proliferation
ex vivo, it is unknown whether these TLR5-induced MDSCs
indeed traffic to the lung-draining LNs where effects on T cell
proliferation would be most relevant. Alternatively, these MDSCs
may also function to dampen effector T cell function in the
tissue.
BACTERIAL PNEUMONIA AND RESOLUTION OF
INFLAMMATION: A NOVEL ROLE FOR TLR-INDUCED MDSCs
Given that a high dose of a bacterial component, LPS, was found
to be a potent stimulus for MDSC development, it seemed logical
to us that bacterial infection of the lung would also trigger MDSC
expansion. Toward this end, the response to the Gram-negative
bacterium, Klebsiella pneumoniae, was studied. K. pneumoniae is
a common pathogen in hospital-acquired pneumonia, particu-
larly in chronically ill subjects (Neuhauser et al., 2003). Bacterial
pneumonia remains a leading cause of morbidity and mortal-
ity (Ware and Matthay, 2000; Lee and Downey, 2001; Abraham,
2003; Mizgerd, 2006, 2008; Tsai and Grayson, 2008; Craig et al.,
2009; Balamayooran et al., 2010). Three million cases of pneu-
monia are reported annually in the United States alone, which
causes 40,000–70,000 deaths each year (Mizgerd, 2008). K. pneu-
moniae induces massive neutrophil influx followed by extensive
lung destruction and TLR4/MyD88 signaling has an important
role in host defense against K. pneumoniae (Chan et al., 2009;
Wieland et al., 2011). A number of studies have documented
the role of both alveolar macrophages and neutrophils in innate
host defense against bacterial pathogens including K. pneumo-
niae (Broug-Holub et al., 1997; Craig et al., 2009). However,
much less is known about the relationship between these two cell
types with regard to bacterial clearance and resolution of lung
inflammation. It is critical that neutrophil-associated (immune-
mediated) pathology be controlled to prevent collateral damage
during defense against the invading pathogen (Lee and Downey,
2001; Abraham, 2003). The problem is, therefore, 2-fold. Bacteria
must be cleared and the ensuing host inflammatory mechanisms
used for bacterial clearance must also be attenuated to prevent
lung tissue damage and high mortality. The significance of this
question can be best appreciated in the context of pneumo-
nia precipitating ALI/ARDS (acute lung injury/acute respiratory
distress syndrome) in which excessive lung inflammation is an
overriding factor of injury suggesting inadequate control by anti-
inflammatory mechanisms.
Defense against pathogenic bacteria involves a set of well-
orchestrated events in which the first step is recognition of the
invading pathogen by the host in which TLRs play an impor-
tant role. A key purpose of sensing pathogens via TLRs is to
rapidly engage an innate immune response to clear the pathogen
(Barton, 2008; Soehnlein and Lindbom, 2010). The cells of the
innate immune system that are well-characterized with respect
to phagocytosis and killing of internalized bacteria are alveo-
lar macrophages and neutrophils (Barton, 2008; Soehnlein and
Lindbom, 2010). Typically, alveolar macrophages participate ini-
tially but are taken over by neutrophils that are rapidly recruited
to the site of infection aided by chemokines, whose major sources
are lung epithelial cells and macrophages (Bergeron et al., 1999).
Neutrophils generate various noxious products including reactive
oxygen species and proteases that are not only harmful for the
pathogen but also for the host’s own cells (Lee and Downey, 2001;
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Abraham, 2003; Mizgerd, 2006, 2008; Balamayooran et al., 2010).
Therefore, once the pathogen is cleared, the immediate next
goal of the host is to mount an appropriate anti-inflammatory
response to limit further neutrophil recruitment. Neutrophils also
have a relatively short life span and rapidly begin to undergo
apoptosis at the site of inflammation. To prevent lung injury,
these apoptotic cells need to be rapidly cleared by phagocytes, a
process termed efferocytosis. It is at this last phase of the host’s
response to infection that the MDSCs step in. As observed with
LPS exposure, after infection, MDSCs do not accumulate rapidly
in the lung but rather develop late after infection (Poe et al., 2013).
This makes perfect sense since the lung MDSCs produce IL-10,
which if produced too early is detrimental to bacterial clearance
since it impedes neutrophil recruitment (Poe et al., 2013). We
showed that the lung MDSCs efficiently efferocytose apoptotic
neutrophils, which is aided by IL-10 produced by the MDSCs.
The successful clearance of pathogens, dampening of neutrophil
infiltration and clearance of dead neutrophils ultimately restores
tissue homeostasis.
In the context of cancer, MDSCs have been shown to pro-
mote the development of regulatory T cells (Tregs) (Nagaraj et al.,
2013). Whether this is also true for lung MDSCs during infec-
tion remains to be determined. However, Tregs were implicated
in suppression of lung inflammation in a model of LPS-induced
lung injury (D’Alessio et al., 2009).
TLR-INDUCED LUNG MDSC DEVELOPMENT AND THE
JAK/STAT PATHWAY
GM-CSF has been implicated in innate immune responses in
the lung in response to LPS (Bozinovski et al., 2002). In vitro,
the combination of LPS and GM-CSF induces differentiation of
lin-progenitor cells into MDSCs, which suggests co-operation
between TLR/MyD88 and Jak2/STAT5 pathways in MDSC devel-
opment (Arora et al., 2010). LPS-induced MDSCs in the lung
produce GM-CSF and IL-6, which have the ability to acti-
vate STAT5 and STAT3, respectively, in cells in an autocrine or
paracrine fashion. STAT5 activation promotes MDSC survival
(Condamine and Gabrilovich, 2011). Jak2/STAT3 signaling has
been also shown to play a crucial role in tumor-associated MDSC
generation (Nefedova et al., 2004; Condamine and Gabrilovich,
2011). Autocrine IL-6-induced STAT3 signaling downstream
of Hsp72/TLR2 was implicated in MDSC-suppressive function
(Chalmin et al., 2010). In our studies, neutralization of IL-6
blunted MDSC numbers in ex vivo cultures of the cells (Poe et al.,
2013). Collectively, these studies suggest that TLR4 activation by
a high dose of LPS in precursor cells induces GM-CSF and IL-
6 production causing STAT5 and STAT3 activation respectively,
which can support the development and function of MDSCs. In
keeping with the noted antagonism between STAT1 and STAT3,
STAT1-deficient mice were examined in our study for lungMDSC
numbers as compared to wild-type mice after bacterial infec-
tion. Indeed, lung MDSC numbers almost doubled in STAT1−/−
mice in response to bacterial infection with fewer neutrophils
as compared to that in wild-type mice (Poe et al., 2013). These
observations suggest that increasing MDSC numbers via STAT1
inhibition in combination with antibiotics may be beneficial in
the context of non-resolving pneumonia.
MDSC INDUCTION BY PATHOGENS VIS-À-VIS USE OF TLR
AGONISTS IN CANCER
Not only in the lung, in other tissues as well, infection by bacteria,
viruses and parasites can promote MDSC accumulation. Table 1
outlines a comparison of MDSCs that have been detected during
infection by various pathogens and those that are most com-
monly associated with cancer, albeit much less information is
available about the former. The common inducer in both contexts
is inflammation. Upon reviewing currently available informa-
tion it is evident that an important role of MDSCs is to exercise
balance between host-defense-associated inflammation mounted
during an immune response and inflammation-mediated tissue
pathology (Ortega-Gomez et al., 2013). In the case of sepsis,
MDSC development induced by acute phase proteins was shown
to be crucial for control of systemic inflammation and sepsis-
induced mortality (Sander et al., 2010). While our study shows
a beneficial effect of MDSCs in mediating resolution of inflam-
mation during bacterial pneumonia, in the case of infection by
influenza virus, MDSC effector function needs to be regulated by
iNKT cells in the absence of which immune suppression exer-
cised by MDSCs causes increased viral titer and mortality (De
Santo et al., 2008). A recent study has proposed that host sus-
ceptibility to co-infection by viruses and bacteria results not due
to exaggerated activation of some well-described immune path-
ways but due to failure to tolerate excessive tissue damage after
infection (Jamieson et al., 2013). However, since lung MDSCs
have been shown to regulate susceptibility to single infection by
either viruses (De Santo et al., 2008) or bacteria (Poe et al., 2013),
it is possible that MDSCs regulate both inflammation and tis-
sue damage during co-infection via one or more of its mediators.
In this regard, the kinetics of MDSC development post infection
(De Santo et al., 2008; Poe et al., 2013) may dictate the ultimate
outcome.
Similar to our observation of the ability of a combination of
GM-CSF and LPS to induce MDSCs in vitro (Arora et al., 2010),
a combination of IFN-γ and LPS was found to enhance the devel-
opment and activation of bone marrow-derived MDSCs while
simultaneously inhibiting the differentiation of bonemarrow cells
to DCs (Greifenberg et al., 2009). Not only LPS, but various other
danger-associated molecular patterns (DAMPs) such as S100A,
and heat shock proteins released from dying cells that also engage
TLR4 or other TLRs have the potential to promote accumulation
of MDSCs or enhance their function (Cheng et al., 2008; Bunt
et al., 2009). Hsp72 from tumor-derived exosomes was shown
to promote STAT3-dependent immunosuppressive function of
MDSCs in a TLR2/MyD88 dependent manner (Chalmin et al.,
2010). Also, the fact that various pathogens that can activate
diverse TLRs can also promote MDSCs suggests that the ability to
cause MDSC-mediated immunosuppression is not just restricted
to TLR4.
Immunosuppression resulting from TLR engagement is of
particular importance in cancer therapy. In fact, most anti-
cancer strategies involving TLR agonist monotherapy have
proven unsuccessful in clinical trials (Guha, 2012). For example,
in a pre-clinical study, failure of imiquimod, a TLR7 ago-
nist, in antitumor therapy was associated with IL-10-mediated
immunosuppression. IL-10 neutralization significantly enhanced
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Table 1 | MDSCs in cancer and infection.
MDSC
context
Species Infectious
agent
Phenotype Function and mediator(s) References
Cancer Mouse CD11b+Ly6ClowLy6G+CD115+/−
F4/80lowCD124+/− (PMN-MDSC)
Reactive Oxygen Species
(ROS)
Reviewed in Gabrilovich
et al., 2012; Nagaraj et al.,
2013
CD11b+Ly6C+Ly6G−CD115+
F4/80+CD124+ (Mo-MDSC)
Arg1, ROS, NO, and Reactive
Nitrogen Species
Human CD11b+CD33+CD14−HLA-
DRlow/−CD15+
(PMN-MDSC)
Arg1, ROS Reviewed in Filipazzi
et al., 2012; Gabrilovich
et al., 2012
CD11b+CD33+CD14+HLA-
DRlow/−CD15low/−
(Mo-MDSC)
TGF-b
Infection Mouse Bacterial
product/Bacteria
1. CD11b+Ly6GintLy6Clow/−
F4/80+CD115−CD124− (LPS and
Klebsiella pneumoniae)
2. In CF patients and in response
to Pseudomonas aeruginosa
(PMN-MDSCs)
1. (a) Inhibits Th2 function and
allergic inflammation and (b)
Promotes resolution of
inflammation after bacterial
pneumonia
Mediator: IL-10
2. Not described
1. Arora et al., 2010; Poe
et al., 2013
2. Rieber et al., 2012
CD11b+Ly6CintLy6G−
(Mycobacterium bovis)
Traffics to draining lymph node
and inhibits T cell priming but
does not kill bacteria
Mediator: NO
Martino et al., 2010
CD11b+Gr1+ (sepsis) Inhibits Th1 but promotes Th2
responses in the spleen,
controls systemic
inflammation and
sepsis-induced mortality
Mediator: IL-10
Delano et al., 2007;
Sander et al., 2010
Virus CD11b+Gr1+F4/80+ (Influenza
A)
Inhibition of anti-viral immune
responses Mediators: Arg1,
NO and IL-10
De Santo et al., 2008;
Jeisy-Scott et al., 2011
Parasite CD11b+Gr1+ Mediator: NO Reviewed in Van
Ginderachter et al.,
2010
CD11bhiLy6ChiF4/80int
(Leishmania major )
Kills parasites and inhibits T
cell proliferation
Mediator: NO
Pereira et al., 2011
the efficacy of imiquimod (Lu et al., 2010). In contrast, use
of TLR agonists in combination with a cancer vaccination
approach or chemotherapy has yielded more promising results
toward the induction of anti-tumor CTL responses (Ridnour
et al., 2013). Most importantly, while TLR signaling and MDSCs
portend poor prognosis for cancers (Ridnour et al., 2013),
they appear to be beneficial in regulating tissue inflamma-
tion in the lung (Arora et al., 2010; Poe et al., 2013) or sys-
temic inflammation during polymicrobial sepsis (Sander et al.,
2010).
CONCLUDING REMARKS
TLR signaling elicited by pathogens or by components of
pathogens in concert with signals imparted by growth factors
such as GM-CSF and IFN-γ has the potential to induce MDSCs
in different organs including the lung. MDSCs can be either
beneficial or detrimental to the host depending on the infec-
tious agent, involved organ and mediator(s) released. High LPS
dose or bacterial infection elicits MDSCs in the lung that play
an important role in regulating immune response in the context
of diverse pulmonary inflammatory conditions such as allergic
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airway inflammation and bacterial pneumonia. These TLR4-
induced MDSCs accumulate with delayed kinetics after high dose
LPS exposure or bacterial infection and have features of PMN-
MDSCs. The MDSCs can suppress Th2 effector function and
efferocytose apoptotic neutrophils and the common mediator
involved is IL-10. The net outcome in each case is resolution of
inflammation. Thus, a possible therapeutic approach for non-
resolving pneumonia is boosting MDSC numbers via STAT1
inhibition in combination with antibiotics where suppression
of unremitting inflammation along with complete elimination
of the infectious agent is the desired goal. Unquestionably, a
fertile area of future research is to understand context-specific
function of MDSCs to suppress or stimulate them for therapeutic
benefits.
ACKNOWLEDGMENTS
This work was supported by US National Institutes of Health
grants HL 077430 and AI 048927 (to Anuradha Ray), AI
100012 (to Prabir Ray), and HL 113956 (to Anuradha Ray and
Prabir Ray).
REFERENCES
Abraham, E. (2003). Neutrophils
and acute lung injury. Crit. Care
Med. 31, S195–S199. doi: 10.1097/
01.CCM.0000057843.47705.E8
Arora, M., Poe, S. L., Oriss, T. B.,
Krishnamoorthy, N., Yarlagadda,
M., Wenzel, et al. (2010).
TLR4/MyD88-induced CD11b+Gr-
1 int F4/80+ non-migratory
myeloid cells suppress Th2
effector function in the lung.
Mucosal Immunol. 3, 578–593. doi:
10.1038/mi.2010.41
Balamayooran, G., Batra, S., Fessler, M.
B., Happel, K. I., and Jeyaseelan, S.
(2010). Mechanisms of neutrophil
accumulation in the lungs against
bacteria.Am. J. Respir. Cell Mol. Biol.
43, 5–16. doi: 10.1165/rcmb.2009-
0047TR
Barton, G. M. (2008). A calculated
response: control of inflammation
by the innate immune system.
J. Clin. Invest. 118, 413–420. doi:
10.1172/JCI34431
Bergeron, Y., Deslauriers, A. M.,
Ouellet, N., Gauthier, M. C., and
Bergeron, M. G. (1999). Influence of
cefodizime on pulmonary inflam-
matory response to heat-killed
Klebsiella pneumoniae in mice.
Antimicrob. Agents Chemother. 43,
2291–2294.
Bozinovski, S., Jones, J. E., Vlahos, R.,
Hamilton, J. A., and Anderson, G. P.
(2002). Granulocyte/macrophage-
colony-stimulating factor
(GM-CSF) regulates lung innate
immunity to lipopolysaccharide
through Akt/Erk activation of
NFkappa B and AP-1 in vivo. J. Biol.
Chem. 277, 42808–42814. doi:
10.1074/jbc.M207840200
Broug-Holub, E., Toews, G. B., van
Iwaarden, J. F., Strieter, R. M.,
Kunkel, S. L., Paine, R. 3rd., et al.
(1997). Alveolar macrophages
are required for protective pul-
monary defenses in murine
Klebsiella pneumonia: elimina-
tion of alveolar macrophages
increases neutrophil recruitment
but decreases bacterial clearance
and survival. Infect. Immun. 65,
1139–1146.
Bunt, S. K., Clements, V. K., Hanson,
E. M., Sinha, P., and Ostrand-
Rosenberg, S. (2009). Inflammation
enhances myeloid-derived sup-
pressor cell cross-talk by signaling
through Toll-like receptor 4.
J. Leukoc. Biol. 85, 996–1004. doi:
10.1189/jlb.0708446
Chalmin, F., Ladoire, S., Mignot,
G., Vincent, J., Bruchard, M.,
Remy-Martin, J. P. et al. (2010).
Membrane-associated Hsp72 from
tumor-derived exosomes mediates
STAT3-dependent immunosup-
pressive function of mouse and
human myeloid-derived sup-
pressor cells. J. Clin. Invest. 120,
457–471. doi: 10.1172/JCI40483
Chan, Y. R., Liu, J. S., Pociask, D.
A., Zheng, M., Mietzner, T. A.,
Berger, T. et al. (2009). Lipocalin
2 is required for pulmonary host
defense against Klebsiella infection.
J. Immunol. 182, 4947–4956. doi:
10.4049/jimmunol.0803282
Chauveau, C., Remy, S., Royer, P.
J., Hill, M., Tanguy-Royer, S.,
Hubert, F. X. et al. (2005). Heme
oxygenase-1 expression inhibits
dendritic cell maturation and
proinflammatory function but con-
serves IL-10 expression. Blood 106,
1694–1702. doi: 10.1182/blood-
2005-02-0494
Cheng, P., Corzo, C. A., Luetteke, N.,
Yu, B., Nagaraj, S., Bui, M. M., et al.
(2008). Inhibition of dendritic cell
differentiation and accumulation of
myeloid-derived suppressor cells in
cancer is regulated by S100A9 pro-
tein. J. Exp. Med. 205, 2235–2249.
doi: 10.1084/jem.20080132
Condamine, T., and Gabrilovich, D. I.
(2011). Molecular mechanisms reg-
ulating myeloid-derived suppressor
cell differentiation and function.
Trends Immunol. 32, 19–25. doi:
10.1016/j.it.2010.10.002
Craig, A., Mai, J., Cai, S., and
Jeyaseelan, S. (2009). Neutrophil
recruitment to the lungs dur-
ing bacterial pneumonia. Infect.
Immun. 77, 568–575. doi:
10.1128/IAI.00832-08
D’Alessio, F. R., Tsushima, K.,
Aggarwal, N. R., West, E. E., Willett,
M. H., Britos, M. F., et al. (2009).
CD4+CD25+Foxp3+ Tregs resolve
experimental lung injury in mice
and are present in humans with
acute lung injury. J. Clin. Invest. 119,
2898–2913. doi: 10.1172/JCI36498
Debes, G. F., Arnold, C. N., Young,
A. J., Krautwald, S., Lipp, M., Hay,
J. B., et al. (2005). Chemokine
receptor CCR7 required for T lym-
phocyte exit from peripheral tis-
sues.Nat. Immunol. 6, 889–894. doi:
10.1038/ni1238
Delano, M. J., Scumpia, P. O.,
Weinstein, J. S., Coco, D., Nagaraj,
S., Kelly-Scumpia, K. M., et al.
(2007). MyD88-dependent
expansion of an immature
GR-1(+)CD11b(+) popula-
tion induces T cell suppression
and Th2 polarization in sepsis.
J. Exp. Med. 204, 1463–1474. doi:
10.1084/jem.20062602
Delayre-Orthez, C., Becker, J., de Blay,
F., Frossard, N., and Pons, F. (2005).
Exposure to endotoxins during
sensitization prevents further
endotoxin-induced exacerbation of
airway inflammation in a mouse
model of allergic asthma. Int. Arch.
Allergy Immunol. 138, 298–304. doi:
10.1159/000088867
De Santo, C., Salio, M., Masri, S. H.,
Lee, L. Y., Dong, T., Speak, A.
O., et al. (2008). Invariant NKT
cells reduce the immunosuppres-
sive activity of influenza A virus-
induced myeloid-derived suppres-
sor cells in mice and humans.
J. Clin. Invest. 118, 4036–4048. doi:
10.1172/JCI36264
De Wilde, V., Van Rompaey, N.,
Hill, M., Lebrun, J. F., Lemaitre,
P., Lhomme, F., et al. (2009).
Endotoxin-induced myeloid-
derived suppressor cells inhibit
alloimmune responses via
heme oxygenase-1. Am. J.
Transplant. 9, 2034–2047. doi:
10.1111/j.1600-6143.2009.02757.x
Eisenbarth, S. C., Piggott, D. A.,
Huleatt, J. W., Visintin, I., Herrick,
C. A., and Bottomly, K. (2002).
Lipopolysaccharide-enhanced, toll-
like receptor 4-dependent T helper
cell type 2 responses to inhaled anti-
gen. J. Exp. Med. 196, 1645–1651.
doi: 10.1084/jem.20021340
Filipazzi, P., Huber, V., and Rivoltini,
L. (2012). Phenotype, func-
tion and clinical implications of
myeloid-derived suppressor cells in
cancer patients. Cancer Immunol.
Immunother. 61, 255–263. doi:
10.1007/s00262-011-1161-9
Gabrilovich, D. I., and Nagaraj, S.
(2009). Myeloid-derived suppressor
cells as regulators of the immune
system. Nat. Rev. Immunol. 9,
162–174. doi: 10.1038/nri2506
Gabrilovich, D. I., Ostrand-Rosenberg,
S., and Bronte, V. (2012).
Coordinated regulation of
myeloid cells by tumours. Nat.
Rev. Immunol. 12, 253–268. doi:
10.1038/nri3175
Gerhold, K., Avagyan, A., Reichert,
E., Blumchen, K., Wahn, U.,
and Hamelmann, E. (2008).
Lipopolysaccharides modulate
allergen-specific immune regula-
tion in a murine model of mucosal
tolerance induction. Int. Arch.
Allergy Immunol. 147, 25–34. doi:
10.1159/000128583
Gerhold, K., Blumchen, K., Bock, A.,
Seib, C., Stock, P., Kallinich, T.,
et al. (2002). Endotoxins prevent
murine IgE production, T(H)2
immune responses, and devel-
opment of airway eosinophilia
but not airway hyperreactivity.
J. Allergy Clin. Immunol. 110,
110–116. doi: 10.1067/mai.2002.
125831
Greifenberg, V., Ribechini, E., Rossner,
S., and Lutz, M. B. (2009). Myeloid-
derived suppressor cell activation
by combined LPS and IFN-gamma
treatment impairs DC development.
Eur. J. Immunol. 39, 2865–2876. doi:
10.1002/eji.200939486
Guha, M. (2012). Anticancer TLR
agonists on the ropes. Nat. Rev.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org September 2013 | Volume 3 | Article 52 | 6
Ray et al. MDSCs and resolution of inflammation
Drug Discov. 11, 503–505. doi:
10.1038/nrd3775
Hand, T. W., Cui, W., Jung, Y. W.,
Sefik, E., Joshi, N. S., Chandele,
A. et al. (2010). Differential effects
of STAT5 and PI3K/AKT signal-
ing on effector and memory CD8
T-cell survival. Proc. Natl. Acad.
Sci. U.S.A. 107, 16601–16606. doi:
10.1073/pnas.1003457107
Hu, H., Huston, G., Duso, D., Lepak,
N., Roman, E., and Swain, S. L.
(2001). CD4(+) T cell effectors can
becomememory cells with high effi-
ciency and without further divi-
sion.Nat. Immunol. 2, 705–710. doi:
10.1038/90643
Huang, B., Pan, P. Y., Li, Q., Sato, A.
I., Levy, D. E., Bromberg, J., et al.
(2006). Gr-1+CD115+ immature
myeloid suppressor cells mediate
the development of tumor-induced
T regulatory cells and T-cell anergy
in tumor-bearing host. Cancer Res.
66, 1123–1131. doi: 10.1158/0008-
5472.CAN-05-1299
Jamieson, A. M., Pasman, L., Yu, S.,
Gamradt, P., Homer, R. J., Decker,
T., et al. (2013). Role of tis-
sue protection in lethal respiratory
viral-bacterial coinfection. Science
34, 1230–1234. doi: 10.1126/sci-
ence.1233632
Jeisy-Scott, V., Davis, W. G., Patel, J.
R., Bowzard, J. B., Shieh, W. J.,
and Zaki, S. R. (2011). Increased
MDSC accumulation and Th2
biased response to influenza A virus
infection in the absence of TLR7
in mice. PLoS ONE 6:e25242. doi:
10.1371/journal.pone.0025242
Kawai, T., and Akira, S. (2010). The role
of pattern-recognition receptors in
innate immunity: update on Toll-
like receptors. Nat. Immunol. 11,
373–384. doi: 10.1038/ni.1863
Kondo, T., Kawai, T., and Akira,
S. (2012). Dissecting negative
regulation of Toll-like recep-
tor signaling. Trends Immunol.
33, 449–458. doi: 10.1016/j.it.
2012.05.002
Lee, W. L., and Downey, G. P. (2001).
Neutrophil activation and acute
lung injury. Curr. Opin. Crit. Care
7, 1–7. doi: 10.1097/00075198-
200102000-00001
Lemaitre, B., Nicolas, E., Michaut, L.,
Reichhart, J. M., and Hoffmann,
J. A. (1996). The dorsoventral
regulatory gene cassette spat-
zle/Toll/cactus controls the potent
antifungal response in Drosophila
adults. Cell 86, 973–983. doi:
10.1016/S0092-8674(00)80172-5
Liew, F. Y., Xu, D., Brint, E. K., and
O’Neill, L. A. (2005). Negative
regulation of toll-like receptor-
mediated immune responses. Nat.
Rev. Immunol. 5, 446–458. doi:
10.1038/nri1630
Lu, H., Wagner, W. M., Gad, E., Yang,
Y., Duan, H., Amon, L. M., et al.
(2010). Treatment failure of a TLR-7
agonist occurs due to self-regulation
of acute inflammation and can
be overcome by IL-10 blockade.
J. Immunol. 184, 5360–5367. doi:
10.4049/jimmunol.0902997
Martino, A., Badell, E., Abadie, V.,
Balloy, V., Chignard, M., Mistou,
M. Y., et al. (2010). Mycobacterium
bovis bacillus Calmette-Guerin vac-
cination mobilizes innate myeloid-
derived suppressor cells restraining
in vivo T cell priming via IL-1R-
dependent nitric oxide production.
J. Immunol. 184, 2038–2047. doi:
10.4049/jimmunol.0903348
Massberg, S., Schaerli, P., Knezevic-
Maramica, I., Kollnberger, M.,
Tubo, N., Moseman, E. A., et al.
(2007). Immunosurveillance
by hematopoietic progenitor
cells trafficking through blood,
lymph, and peripheral tis-
sues. Cell 131, 994–1008. doi:
10.1016/j.cell.2007.09.047
Medzhitov, R., Preston-Hurlburt,
P., and Janeway, C. A. Jr. (1997).
A human homologue of the
Drosophila Toll protein signals
activation of adaptive immu-
nity. Nature 388, 394–397. doi:
10.1038/41131
Mizgerd, J. P. (2006). Lung
infection–a public health pri-
ority. PLoS Med. 3:e76. doi:
10.1371/journal.pmed.0030076
Mizgerd, J. P. (2008). Acute lower
respiratory tract infection. N.
Engl. J. Med. 358, 716–727. doi:
10.1056/NEJMra074111
Nagai, Y., Garrett, K. P., Ohta, S.,
Bahrun, U., Kouro, T., Akira, S.,
et al. (2006). Toll-like receptors on
hematopoietic progenitor cells stim-
ulate innate immune system replen-
ishment. Immunity 24, 801–812.
doi: 10.1016/j.immuni.2006.04.008
Nagaraj, S., Youn, J. I., and Gabrilovich,
D. I. (2013). Reciprocal Relationship
between Myeloid-Derived
Suppressor Cells and T Cells.
J. Immunol. 191, 17–23. doi:
10.4049/jimmunol.1300654
Nefedova, Y., Huang, M., Kusmartsev,
S., Bhattacharya, R., Cheng,
P., Salup, R., et al. (2004).
Hyperactivation of STAT3 is
involved in abnormal differenti-
ation of dendritic cells in cancer.
J. Immunol. 172, 464–474.
Neuhauser, M. M., Weinstein, R.
A., Rydman, R., Danziger, L. H.,
Karam, G., and Quinn, J. P. (2003).
Antibiotic resistance among gram-
negative bacilli in US intensive
care units: implications for fluoro-
quinolone use. JAMA 289, 885–888.
doi: 10.1001/jama.289.7.885
Oriss, T. B., Ostroukhova, M., Seguin-
Devaux, C., Dixon-McCarthy, B.,
Stolz, D. B., Watkins, S. C., et al.
(2005). Dynamics of dendritic cell
phenotype and interactions with
CD4+ T cells in airway inflamma-
tion and tolerance. J. Immunol. 174,
854–863.
Ortega-Gomez, A., Perretti, M., and
Soehnlein, O. (2013). Resolution
of infllammation:an integrated
view. EMBO Mol. Med. 5,
661–674. doi: 10.1002/emmm.
201202382
Ostrand-Rosenberg, S., and Sinha, P.
(2009). Myeloid-derived suppressor
cells: linking inflammation and can-
cer. J. Immunol. 182, 4499–4506.
doi: 10.4049/jimmunol.0802740
Peranzoni, E., Zilio, S., Marigo,
I., Dolcetti, L., Zanovello, P.,
Mandruzzato, S., et al. (2010).
Myeloid-derived suppressor cell
heterogeneity and subset definition.
Curr. Opin. Immunol. 22, 238–244.
doi: 10.1016/j.coi.2010.01.021
Pereira, W. F., Ribeiro-Gomes, F. L.,
Guillermo, L. V., Vellozo, N. S.,
Montalvao, F., and Dosreis, G. A.
(2011). Myeloid-derived suppres-
sor cells help protective immu-
nity to Leishmania major infection
despite suppressed T cell responses.
J. Leukoc. Biol. 90, 1191–1197. doi:
10.1189/jlb.1110608
Poe, S. L., Arora, M., Oriss, T. B.,
Yarlagadda, M., Isse, K., Khare,
A., et al. (2013). STAT1-regulated
lung MDSC-like cells produce
IL-10 and efferocytose apoptotic
neutrophils with relevance in res-
olution of bacterial pneumonia.
Mucosal Immunol. 6, 189–199. doi:
10.1038/mi.2012.62
Poltorak, A., He, X., Smirnova, I., Liu,
M. Y., Van Huffel, C., Du, X., et al.
(1998). Defective LPS signaling in
C3H/HeJ and C57BL/10ScCr mice:
mutations in Tlr4 gene. Science
282, 2085–2088. doi: 10.1126/sci-
ence.282.5396.2085
Qureshi, S. T., Lariviere, L., Leveque,
G., Clermont, S., Moore, K. J.,
Gros, P., et al. (1999). Endotoxin-
tolerant mice have mutations
in Toll-like receptor 4 (Tlr4).
J. Exp. Med. 189, 615–625. doi:
10.1084/jem.189.4.615
Ricchetti, G. A., Williams, L. M.,
and Foxwell, B. M. (2004). Heme
oxygenase 1 expression induced
by IL-10 requires STAT-3 and
phosphoinositol-3 kinase and is
inhibited by lipopolysaccharide.
J. Leukoc. Biol. 76, 719–726. doi:
10.1189/jlb.0104046
Ridnour, L. A., Cheng, R. Y., Switzer,
C. H., Heinecke, J. L., Ambs, S.,
Glynn, S., et al. (2013). Molecular
pathways: toll-like receptors in the
tumor microenvironment–poor
prognosis or new therapeu-
tic opportunity. Clin. Cancer
Res. 19, 1340–1346. doi:
10.1158/1078-0432.CCR-12-0408
Rieber, N., Brand, A., Hector, A.,
Graepler-Mainka, U., Ost, M.,
Schafer, I., et al. (2012). Flagellin
induces myeloid-derived suppres-
sor cells:implications for cystic
fibrosis infection in cystic fibrosis
lung disease. J. Immunol. 190,
1276–1284. doi: 10.4049/jimmunol.
1202144
Rittirsch, D., Flierl, M. A., and Ward,
P. A. (2008). Harmful molecu-
lar mechanisms in sepsis. Nat.
Rev. Immunol. 8, 776–787. doi:
10.1038/nri2402
Rodriguez, D., Keller, A. C., Faquim-
Mauro, E. L., de Macedo, M. S.,
Cunha, F. Q., Lefort, J., et al.
(2003). Bacterial lipopolysaccharide
signaling through Toll-like receptor
4 suppresses asthma-like responses
via nitric oxide synthase 2 activity.
J. Immunol. 171, 1001–1008.
Rodriguez, P. C., Hernandez, C. P.,
Quiceno, D., Dubinett, S. M.,
Zabaleta, J., Ochoa, J. B., et al.
(2005). Arginase I in myeloid
suppressor cells is induced by
COX-2 in lung carcinoma.
J. Exp. Med. 202, 931–939. doi:
10.1084/jem.20050715
Rotta, G., Edwards, E. W., Sangaletti,
S., Bennett, C., Ronzoni, S.,
Colombo, M. P., et al. (2003).
Lipopolysaccharide or whole
bacteria block the conversion
of inflammatory monocytes
into dendritic cells in vivo.
J. Exp. Med. 198, 1253–1263.
doi: 10.1084/jem.20030335
Sander, L. E., Sackett, S. D., Dierssen,
U., Beraza, N., Linke, R. P.,
and Muller, M. (2010). Hepatic
acute-phase proteins control
innate immune responses during
infection by promoting myeloid-
derived suppressor cell function.
J. Exp. Med. 207, 1453–1464. doi:
10.1084/jem.20091474
Serafini, P., Mgebroff, S., Noonan, K.,
and Borrello, I. (2008). Myeloid-
derived suppressor cells promote
cross-tolerance in B-cell lymphoma
by expanding regulatory T cells.
Cancer Res. 68, 5439–5449. doi:
10.1158/0008-5472.CAN-07-6621
Soehnlein, O., and Lindbom, L. (2010).
Phagocyte partnership during the
onset and resolution of inflam-
mation. Nat. Rev. Immunol. 10,
427–439. doi: 10.1038/nri2779
Frontiers in Cellular and Infection Microbiology www.frontiersin.org September 2013 | Volume 3 | Article 52 | 7
Ray et al. MDSCs and resolution of inflammation
Srivastava, M. K., Sinha, P., Clements,
V. K., Rodriguez, P., and
Ostrand-Rosenberg, S. (2010).
Myeloid-derived suppressor
cells inhibit T-cell activation
by depleting cystine and cys-
teine. Cancer Res. 70, 68–77. doi:
10.1158/0008-5472.CAN-09-2587
Tsai, K. S., and Grayson, M. H. (2008).
Pulmonary defense mechanisms
against pneumonia and sepsis. Curr.
Opin. Pulm. Med. 14, 260–265. doi:
10.1097/MCP.0b013e3282f76457
Van Ginderachter, J. A., Beschin, A.,
De Baetselier, P., and Raes, G.
(2010). Myeloid-derived suppressor
cells in parasitic infections. Eur.
J. Immunol. 40, 2976–2985. doi:
10.1002/eji.201040911
Ware, L. B., and Matthay, M. A.
(2000). The acute respiratory
distress syndrome. N. Engl.
J. Med. 342, 1334–1349. doi:
10.1056/NEJM200005043421806
Wieland, C. W., van Lieshout, M.
H., Hoogendijk, A. J., and van
der Poll, T. (2011). Host defense
during Klebsiella pneumonia
relies on hematopoietic expressed
TLR4 and TLR2. Eur. Respir. J. 37,
848–857. doi: 10.1183/09031936.
00076510
Wofford, J. A., Wieman, H. L., Jacobs,
S. R., Zhao, Y., and Rathmell, J.
C. (2008). IL-7 promotes Glut1
trafficking and glucose uptake
via STAT5-mediated activation
of Akt to support T-cell sur-
vival. Blood 111, 2101–2111. doi:
10.1182/blood-2007-06-096297
Yang, L., Huang, J., Ren, X., Gorska,
A. E., Chytil, A., Aakre, M., et al.
(2008). Abrogation of TGF beta
signaling in mammary carci-
nomas recruits Gr-1+CD11b+
myeloid cells that promote metas-
tasis. Cancer Cell 13, 23–35. doi:
10.1016/j.ccr.2007.12.004
Zhang, D. H., Cohn, L., Ray, P.,
Bottomly, K., and Ray, A. (1997).
Transcription factor GATA-3
is differentially expressed in
murine Th1 and Th2 cells and
controls Th2-specific expression
of the interleukin-5 gene. J. Biol.
Chem. 272, 21597–21603. doi:
10.1074/jbc.272.34.21597
Zheng, W., and Flavell, R. A. (1997).
The transcription factor GATA-
3 is necessary and sufficient
for Th2 cytokine gene expres-
sion in CD4 T cells. Cell 89,
587–596. doi: 10.1016/S0092-8674
(00)80240-8
Zhu, J., Cote-Sierra, J., Guo, L., and
Paul, W. E. (2003). Stat5 activa-
tion plays a critical role in Th2
differentiation. Immunity 19,
739–748. doi: 10.1016/S1074-7613
(03)00292-9
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 31 July 2013; accepted: 27
August 2013; published online: 18
September 2013.
Citation: Ray A, Chakraborty K and Ray
P (2013) Immunosuppressive MDSCs
induced by TLR signaling during infec-
tion and role in resolution of inflamma-
tion. Front. Cell. Infect. Microbiol. 3:52.
doi: 10.3389/fcimb.2013.00052
This article was submitted to the jour-
nal Frontiers in Cellular and Infection
Microbiology.
Copyright © 2013 Ray, Chakraborty
and Ray. This is an open-access arti-
cle distributed under the terms of
the Creative Commons Attribution
License (CC BY). The use, distribu-
tion or reproduction in other forums
is permitted, provided the original
author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distri-
bution or reproduction is permitted
which does not comply with these
terms.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org September 2013 | Volume 3 | Article 52 | 8
